非侵入性检测生物标志物在前列腺癌诊断中的应用  

Administration of non-invasive detection biomarkers for prostate cancer diagnosis

作　　者：王科[1] 张学宝 王振林[1] 赵凯[1] 张宗亮[1] 李晨[1] 朱冠群[1] Wang Ke;Zhang Xuebao;Wang Zhenlin;Zhao Kai;Zhang Zongliang;Li Chen;Zhu Guanqun(Department of Urology,Affiliated Hospital of Qingdao University,Shandong,Qingdao 266000,China;Department of Urology,Yantai Yuhuangding Hospital,Shandong,Yantai 264000,China)

机构地区：[1]青岛大学附属医院泌尿外科,山东青岛266000 [2]烟台毓璜顶医院泌尿外科,山东烟台264000

出　　处：《肿瘤综合治疗电子杂志》2021年第1期70-74,共5页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：国家自然科学基金项目(31971191)。

摘　　要：作为一种肿瘤标志物,前列腺特异性抗原(prostate-specific antigen,PSA)已被广泛应用于前列腺癌的诊断。但PSA的特异性较低,由PSA升高导致了大量非必要的前列腺穿刺检查。考虑到PSA的局限性和前列腺穿刺活检的侵入性,目前已有多种血清和尿液生物标志物被应用于前列腺癌的诊断。本文对可用于诊断前列腺癌的生物标志物进行了全面综述,包括4-激肽释放酶评分、前列腺健康指数、前列腺癌抗原3、SelectMDx及Exosome Dx。这些生物标志物可以提高前列腺癌的诊断率,减少前列腺癌的过度治疗。然而,生物标志物能否被列为前列腺癌筛查诊断的常规检查项目,仍需要更多的临床试验提供依据。Prostate-specific antigen(PSA),as a tumor marker,has been widely used for diagnosis of prostate cancer.Due to little specificity of PSA,unessential prostate biopsy was increased.Because of limitation of PSA detection and invasion of prostate biopsy,some innovative biomarkers were used for diagnosis of prostate cancer.In this study,we reviewed various prostate cancer biomarkers,such as four kallikrein protein biomarkers score,prostate health index,prostate cancer antigen 3,SelectMDx and Exosome Dx,which can improve diagnosis of prostate cancer and decrease overtreatment.However,more data and further clinical trial are needed for assessing these biomarkers to be routine examinations.

关 键 词：生物标志物 前列腺癌 非侵入性检查 

分 类 号：R737.25[医药卫生—肿瘤]